prediction

From 4Q onward, price increase effects, overseas coverage expansion, and securing bio cost competitiveness through collaboration with ADM are expected.

A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.

4분기 이후 판가 인상 효과와 해외 커버리지 확장, 그리고 ADM과의 협업을 통한 바이오 원가 경쟁력 확보가 기대됩니다.
companyreportPublished 2026-11-10 Read source

Related claims